US 12,152,034 B2
FGFR inhibitors and methods of making and using the same
André Lescarbeau, Cambridge, MA (US); Jethro Beamish-Cook, Cambridge (GB); Zoe Prentice, Cambridge (GB); Thomas Kendall, Cambridge (GB); Aaron Dumas, Hertfordshire (GB); Elisabeth Isaak, Hertfordshire (GB); Piera Trinchera, Hertfordshire (GB); Oleksandr Zhurakovskyi, Hertfordshire (GB); and Osama Suleiman, Cambridge (GB)
Assigned to Relay Therapeutics, Inc., Cambridge, MA (US)
Filed by Relay Therapeutics, Inc., Cambridge, MA (US)
Filed on Nov. 18, 2021, as Appl. No. 17/455,507.
Claims priority of provisional application 63/115,319, filed on Nov. 18, 2020.
Prior Publication US 2022/0194946 A1, Jun. 23, 2022
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 19 Claims
 
1. A crystalline solid form of a compound of Formula I-1:

OG Complex Work Unit Chemistry
wherein the crystalline solid form is characterized by a powder X-ray diffraction pattern with at least two characteristic peaks, in degrees 2θ, each selected from the group consisting of:
 
Angle (2θ)°
 
 
   7.5
 
  9.2
 
 10.4
 
 11.1
 
 11.8
 
 12.3
 
 12.7
 
 13.2
 
 14.0
 
 14.2
 
 14.4
 
 15.2
 
 15.6
 
 17.5
 
 18.2
 
 18.5
 
 18.8
 
 19.2
 
 19.5
 
 20.6
 
 21.7
 
 22.9
 
 24.0
 
 24.8
 
 25.5
 
 26.9
 
 28.1 and
 
 29.5,
 
wherein each peak is ±0.2°.